These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36403963)

  • 1. Utility of CD229 as novel marker in measurable residual disease assessment in multiple myeloma-An evidence-based approach.
    Rai S; Das N; Gupta R; Kumar L; Sharma A; Singh S; Prajapati VK
    Int J Lab Hematol; 2023 Apr; 45(2):179-186. PubMed ID: 36403963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.
    Pojero F; Flores-Montero J; Sanoja L; Pérez JJ; Puig N; Paiva B; Bottcher S; van Dongen JJ; Orfao A;
    Cytometry B Clin Cytom; 2016 Jan; 90(1):91-100. PubMed ID: 26130131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies.
    Tembhare PR; Ghogale S; Tauro W; Badrinath Y; Deshpande N; Kedia S; Cherian K; Patkar NV; Chatterjee G; Gujral S; Subramanian PG
    Cytometry B Clin Cytom; 2018 May; 94(3):509-519. PubMed ID: 29316178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab.
    Soh KT; Tario JD; Hahn T; Hillengass J; McCarthy PL; Wallace PK
    Cytometry B Clin Cytom; 2021 Jul; 100(4):497-508. PubMed ID: 33017079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab-Treated Patients With Multiple Myeloma.
    Yang S; Hu Q; Wang X; Qiao S; Qi C; Jin H; Zhong Y
    Int J Lab Hematol; 2024 Sep; ():. PubMed ID: 39267340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of polyclonal plasma cells and post-therapy immunomodulation in measurable residual disease assessment in multiple myeloma.
    Das N; Dahiya M; Gupta R; Kumar L; Sharma A; Rai S; Singh S; Prajapati VK; Sahoo RK; Gogia A
    Cytometry B Clin Cytom; 2022 May; 102(3):209-219. PubMed ID: 35389550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry.
    Sato K; Okazuka K; Ishida T; Sakamoto J; Kaneko S; Nashimoto J; Uto Y; Ogura M; Yoshiki Y; Abe Y; Maeda A; Hamazaki H; Tsukada N; Hiragohri Y; Suzuki K
    Ann Hematol; 2021 Dec; 100(12):2989-2995. PubMed ID: 34430990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.
    Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK
    Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma.
    Atanackovic D; Panse J; Hildebrandt Y; Jadczak A; Kobold S; Cao Y; Templin J; Meyer S; Reinhard H; Bartels K; Lajmi N; Zander AR; Marx AH; Bokemeyer C; Kröger N
    Haematologica; 2011 Oct; 96(10):1512-20. PubMed ID: 21606160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.
    Yousef S; Kovacsovics-Bankowski M; Salama ME; Bhardwaj N; Steinbach M; Langemo A; Kovacsovics T; Marvin J; Binder M; Panse J; Kröger N; Luetkens T; Atanackovic D
    Hum Vaccin Immunother; 2015; 11(7):1606-11. PubMed ID: 26001047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The Significance of CD319 and CD269 in the Detection of Immunophenotyping and Minimal Residual Disease in Multiple Myeloma Patients].
    Chu B; Wang YT; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Bao L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1195-1202. PubMed ID: 34362502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison and analysis of minimal residual disease in multiple myeloma patients detected by 4-color and 8-color fluorescence antibody panels].
    Wang YZ; Lu J; Hao L; Chang Y; He LL; Huang XJ; Liu YR
    Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):272-278. PubMed ID: 28468086
    [No Abstract]   [Full Text] [Related]  

  • 14. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data.
    Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P
    J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunophenotypic characterization of normal and abnormal plasma cells in bone marrow of newly diagnosed multiple myeloma patients.
    Awasthi NP; Mishra S; Gupta G; Kumari S; Bajpayee A; Singh P; Husain N
    Indian J Pathol Microbiol; 2023; 66(2):295-300. PubMed ID: 37077071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow cytometric immunophenotyping of plasma cells across the spectrum of plasma cell proliferative disorders: A fresh insight with pattern-based recognition.
    Das N; Dahiya M; Gupta R; Rai S; Singh S; Prajapati VK; Kumar L; Sharma A; Sahoo RK; Gogia A
    Cytometry B Clin Cytom; 2022 Jul; 102(4):292-302. PubMed ID: 35212134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an unbiased, semi-automated approach for classifying plasma cell immunophenotype following multicolor flow cytometry of bone marrow aspirates.
    Post SR; Post GR; Nikolic D; Owens R; Insuasti-Beltran G
    Cytometry B Clin Cytom; 2018 Sep; 94(5):602-610. PubMed ID: 29573142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study.
    Liu H; Yuan C; Heinerich J; Braylan R; Chang M; Wingard J; Moreb J
    Leuk Lymphoma; 2008 Feb; 49(2):306-14. PubMed ID: 18231918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.
    Muccio VE; Saraci E; Gilestro M; Gattei V; Zucchetto A; Astolfi M; Ruggeri M; Marzanati E; Passera R; Palumbo A; Boccadoro M; Omedè P
    Cytometry B Clin Cytom; 2016 Jan; 90(1):81-90. PubMed ID: 26287276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of minimal residual disease in multiple myeloma patients detected by 8-color panels and next generation flow cytometry].
    Wang XF; Wang TT; Zhang ZY; Zhou HX; Zhang YR; Chen WM; Geng CY
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):512-517. PubMed ID: 31340626
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.